Alpha Tau Medical Ltd

NASDAQ DRTS

Download Data

Alpha Tau Medical Ltd Liabilities to Equity Ratio 3 year CAGR for the quarter ending March 31, 2024

Alpha Tau Medical Ltd Liabilities to Equity Ratio 3 year CAGR is NA for the quarter ending March 31, 2024. The liabilities to equity ratio, also known as the leverage ratio, measures the proportion of a company's total liabilities to its shareholders' equity. It is calculated by dividing the total liabilities by the shareholders' equity. This ratio provides insights into the extent to which a company relies on debt financing compared to equity financing. A higher ratio indicates higher financial leverage, which can amplify both returns and risks for the company's shareholders. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
  • Alpha Tau Medical Ltd Liabilities to Equity Ratio for the quarter ending March 31, 2023 was -164.51, a -61,821.77% change year over year.
  • Alpha Tau Medical Ltd Liabilities to Equity Ratio for the quarter ending March 31, 2022 was 0.27, a 112.04% change year over year.
  • Alpha Tau Medical Ltd Liabilities to Equity Ratio for the quarter ending March 31, 2021 was -2.21, a 69.62% change year over year.
  • Alpha Tau Medical Ltd Liabilities to Equity Ratio for the quarter ending March 31, 2020 was -7.29, a 95.57% change year over year.
NASDAQ: DRTS

Alpha Tau Medical Ltd

CEO Mr. Uzi Sofer
IPO Date March 8, 2021
Location Israel
Headquarters 5 Kiryat Hamada Street, Jerusalem, Israel, 9777605
Employees 121
Sector Healthcare
Industry Biotechnology
Description

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. The company's Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; preclinical or pending clinical studies for brain and other cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. Alpha Tau Medical Ltd. was incorporated in 2015 and is headquartered in Jerusalem, Israel.

Similar companies

TNYA

Tenaya Therapeutics Inc

NA

NA

MNOV

MediciNova Inc

NA

NA

ELYM

Eliem Therapeutics Inc

NA

NA

CYT

Cyteir Therapeutics Inc

NA

NA

HCWB

HCW Biologics Inc

NA

NA

StockViz Staff

September 20, 2024

Any question? Send us an email